Back to Best of AC2017 Session - Practical Issues for Clinicians - Session I - On-Demand
Best of AC2017 Session - Practical Issues for Clinicians - Session I - On-Demand

Best of AC2017 Session - Practical Issues for Clinicians - Session I - On-Demand

Matters Close to the Heart: Cardio-Oncology in Breast Cancer

Therapeutic advancements over recent decades have led to a growing number of breast cancer survivors. However, these successes have been overshadowed by the unintended, and often devastating, cardiac outcomes affecting survivors of breast cancer. Anthracyclines and trastuzumab represent the agents responsible for left ventricular dysfunction and heart failure. In general, healthcare providers are operating in a reactive rather than a proactive manner when monitoring for cardiotoxicity. Ideally, detecting cardiac damage before it results in decline in ejection fraction may lead to better cardiac outcomes. Emerging strategies in prevention and monitoring will be highlighted.

 

Content Area: Patient Management & Therapeutics

 

Secondary Acute Myeloid Leukemia Following Myelodysplastic Syndrome: Induction Strategies Beyond 7+3

AML arising from prior myelodysplastic syndrome (MDS) carries a poor prognosis and is less responsive to conventional anthracycline/cytarabine induction regimens. Treatment-naive patients may be candidates for hypomethylators (HMAs); however, no standard of care exists for patients previously treated with HMAs or those with progressive leukocytosis where initial therapy with HMAs may be inadequate. This presentation will discuss alternative induction strategies for MDS to AML transformation and draw comparisons to 7+3-like inductions when applicable. Treatment options to be discussed include liposomal cytarabine/daunorubicin (CPX-351), high-dose cytarabine/anthracycline combinations, and purine antagonist/high-dose cytarabine combinations.

 

Content Area: Patient Management & Therapeutics

Product Details

This session is from the HOPA 2017 Annual Conference.

Matters Close to the Heart: Cardio-Oncology in Breast Cancer

Speaker: Sandra Cuellar, PharmD BCOP

 

Learning Objectives:

1.      Review the epidemiology of cardiotoxicity in breast cancer patients.

2.      Discuss emerging prevention and monitoring strategies for breast cancer patients receiving cardiotoxic agents.

 

Secondary Acute Myeloid Leukemia Following Myelosysplastic Syndrome: Induction Strategies Beyond 7+3

 

Speaker: Craig Freyer, PharmD BCOP

Learning Objectives:

1.      Recognize differences in response to conventional cytarabine and anthracycline induction regimens for patients with secondary versus de novo acute myeloid leukemia (AML).

2.      Analyze induction outcomes for high-risk secondary AML patients receiving CPX-351 versus 7+3.

3.      Appraise data supporting the use of high-dose cytarabine-based induction regimens with or without purine antagonists for patients with secondary AML.

 

  • List Price: $35.00 USD
  • Member Price: $25.00 USD
Join and Save!
Log into see if you qualify for a lower price.
HOPA members save $10.00 USD or more!
Become a member